title: Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte.
abstract: MR (mineralocorticoid receptor) activation in the heart plays a central role in the development of cardiovascular disease, including heart failure. The MR is present in many cell types within the myocardium, including cardiomyocytes, macrophages and the coronary vasculature. The specific role of the MR in each of these cell types in the initiation and progression of cardiac pathophysiology is not fully understood. Cardiomyocyte MRs are increasingly recognized to play a role in regulating cardiac function, electrical conduction and fibrosis, through direct signal mediation and through paracrine MR-dependent activity. Although MR blockade in the heart is an attractive therapeutic option for the treatment of heart failure and other forms of heart disease, current antagonists are limited by side effects owing to MR inactivation in other tissues (including renal targets). This has led to increased efforts to develop therapeutics that are more selective for cardiac MRs and which may have reduced the occurrence of side effects in non-cardiac tissues. A major clinical consideration in the treatment of cardiovascular disease is of the differences between males and females in the incidence and outcomes of cardiac events. There is clinical evidence that female sensitivity to endogenous MRs is more pronounced, and experimentally that MR-targeted interventions may be more efficacious in females. Given that sex differences have been described in MR signalling in a range of experimental settings and that the MR and oestrogen receptor pathways share some common signalling intermediates, it is becoming increasingly apparent that the mechanisms of MRs need to be evaluated in a sex-selective manner. Further research targeted to identify sex differences in cardiomyocyte MR activation and signalling processes has the potential to provide the basis for the development of cardiac-specific MR therapies that may also be sex-specific.
authors.affiliation: Prince Henry's Institute of Medical Research, Clayton, VIC 3168, Australia.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Bienvenu
authors.forename: Melissa E
authors.initials: ME
authors.lastname: Reichelt
authors.forename: Lea M D
authors.initials: LM
authors.lastname: Delbridge
authors.forename: Morag J
authors.initials: MJ
authors.lastname: Young
mesh_terms: D000818:Animals; D001145:Arrhythmias, Cardiac / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000188:drug therapy; D005260:Female; D005355:Fibrosis; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D008264:Macrophages / Q000502:physiology; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009200:Myocardial Contraction / Q000502:physiology; D017202:Myocardial Ischemia / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D032383:Myocytes, Cardiac / Q000502:physiology*; D018384:Oxidative Stress / Q000502:physiology; D018161:Receptors, Mineralocorticoid / Q000502:physiology*; D012737:Sex Factors; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid